LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

USE OF DABIGATRAN ETEXILATE TO PREVENT STROKE AND THROMBOEMBOLISM IN PATIENTS UNDERGOING LEFT ATRIAL CATHETER ABLATION PROCEDURES FOR PAROXYSMAL OR PERSISTENT (NON-PERMANENT) ATRIAL FIBRILLATION AND LEFT ATRIAL FLUTTER

Photo from wikipedia

Background: Optimal dosing of dabigatran in patients undergoing left atrial (LA) ablation procedures for atrial fibrillation (AF) or LA flutter is unknown. Retrospective data suggest increased bleeding risk with continuous… Click to show full abstract

Background: Optimal dosing of dabigatran in patients undergoing left atrial (LA) ablation procedures for atrial fibrillation (AF) or LA flutter is unknown. Retrospective data suggest increased bleeding risk with continuous dabigatran, and increased embolic risk when interrupted. We sought to confirm

Keywords: atrial fibrillation; patients undergoing; undergoing left; dabigatran; ablation procedures; left atrial

Journal Title: Journal of the American College of Cardiology
Year Published: 2017

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.